155 related articles for article (PubMed ID: 26265351)
1. Heterocyclic Scaffolds in the Design of Peptidomimetic Integrin Ligands: Synthetic Strategies, Structural Aspects, and Biological Activity.
De Marco R; Mazzotti G; Greco A; Gentilucci L
Curr Top Med Chem; 2016; 16(3):343-59. PubMed ID: 26265351
[TBL] [Abstract][Full Text] [Related]
2. Integrin Ligands with α/β-Hybrid Peptide Structure: Design, Bioactivity, and Conformational Aspects.
De Marco R; Tolomelli A; Juaristi E; Gentilucci L
Med Res Rev; 2016 May; 36(3):389-424. PubMed ID: 26777675
[TBL] [Abstract][Full Text] [Related]
3. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction.
Sillerud LO; Larson RS
Curr Protein Pept Sci; 2005 Apr; 6(2):151-69. PubMed ID: 15853652
[TBL] [Abstract][Full Text] [Related]
4. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
Ivachtchenko AV; Ivanenkov YA; Skorenko AV
Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
[TBL] [Abstract][Full Text] [Related]
5. Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands.
Marchini M; Mingozzi M; Colombo R; Guzzetti I; Belvisi L; Vasile F; Potenza D; Piarulli U; Arosio D; Gennari C
Chemistry; 2012 May; 18(20):6195-207. PubMed ID: 22517378
[TBL] [Abstract][Full Text] [Related]
6. 5-aminomethyloxazolidine-2,4-dione hybrid α/β-dipeptide scaffolds as inductors of constrained conformations: Applications to the synthesis of integrin antagonists.
De Marco R; Mazzotti G; Dattoli SD; Baiula M; Spampinato S; Greco A; Gentilucci L
Biopolymers; 2015 Sep; 104(5):636-49. PubMed ID: 26211418
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus inhibition by peptidomimetic integrin antagonists.
Hippenmeyer PJ; Ruminski PG; Rico JG; Lu HS; Griggs DW
Antiviral Res; 2002 Jul; 55(1):169-78. PubMed ID: 12076761
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of amino heterocycle aspartyl protease inhibitors.
Chambers RK; Khan TA; Olsen DB; Sleebs BE
Org Biomol Chem; 2016 Jun; 14(22):4970-85. PubMed ID: 27143279
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of integrin recognition and the inhibition of integrin-mediated cell functions by novel nonpeptidic surrogates of the Arg-Gly-Asp sequence.
Greenspoon N; Hershkoviz R; Alon R; Varon D; Shenkman B; Marx G; Federman S; Kapustina G; Lider O
Biochemistry; 1993 Feb; 32(4):1001-8. PubMed ID: 8093840
[TBL] [Abstract][Full Text] [Related]
10. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
11. Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: receptor-selective somatostatin analogues.
Beierle JM; Horne WS; van Maarseveen JH; Waser B; Reubi JC; Ghadiri MR
Angew Chem Int Ed Engl; 2009; 48(26):4725-9. PubMed ID: 19266506
[TBL] [Abstract][Full Text] [Related]
12. Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dual αVβ3 and α5β1 integrin ligands.
Sernissi L; Trabocchi A; Scarpi D; Bianchini F; Occhiato EG
Bioorg Med Chem; 2016 Feb; 24(4):703-11. PubMed ID: 26753814
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
Ramurthy S; Aikawa M; Amiri P; Costales A; Hashash A; Jansen JM; Lin S; Ma S; Renhowe PA; Shafer CM; Subramanian S; Sung L; Verhagen J
Bioorg Med Chem Lett; 2011 Jun; 21(11):3286-9. PubMed ID: 21543226
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial chemistry: from peptides and peptidomimetics to small organic and heterocyclic compounds.
Nefzi A; Dooley C; Ostresh JM; Houghten RA
Bioorg Med Chem Lett; 1998 Sep; 8(17):2273-8. PubMed ID: 9873527
[TBL] [Abstract][Full Text] [Related]
15. Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.
Zampieri D; Vio L; Fermeglia M; Pricl S; Wünsch B; Schepmann D; Romano M; Mamolo MG; Laurini E
Eur J Med Chem; 2016 Oct; 121():712-726. PubMed ID: 27366902
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in the utility of saturated azaheterocycles in peptidomimetics.
Singh MK; Lakshman MK
Org Biomol Chem; 2022 Feb; 20(5):963-979. PubMed ID: 35018952
[TBL] [Abstract][Full Text] [Related]
17. Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4).
Mungalpara J; Thiele S; Eriksen Ø; Eksteen J; Rosenkilde MM; Våbenø J
J Med Chem; 2012 Nov; 55(22):10287-91. PubMed ID: 23043442
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and analgesic activity of alkylated, reduced and constrained oligoheterocyclic peptidomimetic analogs of Leu-enkephalin.
Hammami S; Mighri Z; Dooley CT; Nefzi A
Bioorg Med Chem Lett; 2014 Sep; 24(18):4482-4485. PubMed ID: 25168746
[TBL] [Abstract][Full Text] [Related]
19. Modulation of αvβ₃- and α₅β₁-integrin-mediated adhesion by dehydro-β-amino acids containing peptidomimetics.
Tolomelli A; Baiula M; Belvisi L; Viola A; Gentilucci L; Troisi S; Dattoli SD; Spampinato S; Civera M; Juaristi E; Escudero M
Eur J Med Chem; 2013 Aug; 66():258-68. PubMed ID: 23811088
[TBL] [Abstract][Full Text] [Related]
20. Evolution in non-peptide α-helix mimetics on the road to effective protein-protein interaction modulators.
Algar S; Martín-Martínez M; González-Muñiz R
Eur J Med Chem; 2021 Feb; 211():113015. PubMed ID: 33423841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
